01 — At a Glance
The Company Building India’s Sewers While Shareholders Pay For It
- 52-Week High / Low₹706 / ₹374
- Q3 FY26 Revenue (Cons.)₹489 Cr
- Q3 FY26 PAT (Cons.)₹78 Cr
- Q3 EPS₹11.35
- Annualised EPS (Q3×4)₹45.4
- Book Value₹297
- Price to Book1.59x
- Debt / Equity0.30x
- Order Book₹9,000 Cr
- Rating (Infomerics)IVR BBB/A3+
The Funny Part: Ramky is building everything — water treatment plants, pharma parks, sewage systems, industrial zones, roads. Meanwhile, the stock has lost 21.4% in the last 6 months. You’d think a company that’s literally building India’s infrastructure would have a slightly better stock chart. You’d be adorably wrong. Order book at ₹9,000 crore. Debt under ₹600 crore. Promoters sitting pretty with 69.8%. And yet, here we are, down 4.3% over a full year. The market is having a laugh.
02 — Introduction
Welcome to Infrastructure: Where Every Win Feels Like A Loss
Ramky Infrastructure Limited is what happens when a Hyderabad-based family decides to build literally everything India needs. Water treatment plants? Check. Sewage systems? Double-check. Industrial parks? Pharma zones? Roads? Trash-to-energy facilities? Sir, we’re gonna need a bigger punch card.
Founded in 1994 as the flagship of the Ramky Group, RIL has grown into a serious infrastructure play with a presence in 23 states, projects across six major sectors, and what management calls “distinct competitive advantage” (which is corporate speak for “we actually finish projects on time, unlike some contractors we all know”).
The numbers, on paper, look respectable. ₹489 crore quarterly revenue. ₹78 crore profit. An order book worth ₹9,000 crores — that’s about 4.9x annual sales, or nearly 3 years of work if nothing else gets signed. A capital structure that went from absolute leverage disaster (₹2,120 crore debt in FY22) to manageable (₹613 crore in Sep 2025). A credit rating upgrade just last month to IVR BBB with stable outlook.
And yet, the stock has decided to politely excuse itself from the party.
In Q3 FY26, consolidated revenue hit ₹489 crore with PAT of ₹78 crore. That’s an 6.5% quarter-on-quarter bump in sales, and a heroic 39.3% jump in profit. Order book sits at ₹9,000 crore, with around 50% of it in operation & maintenance contracts (low-burn, high-visibility cash). The company is bleeding debt and mining for margin. So logically, the stock should be treating itself to a nice little rally. Instead, it’s down. This is not financial advice, but it is comedy.
From the concall (Feb 2026): Management acknowledged “operational execution progressing well” and highlighted recent ₹3,000 crore pharma park concession win (95-year term, 1,000 hectares). Order book to revenue visibility at 1.96x–3.72x, depending on execution pace. Translation: they’re building aggressively, but recognition lags physical completion by 18–24 months.
03 — Business Model: The Three Boring Buckets
EPC + Developer + O&M: The Trifecta Nobody Talks About At Dinner Parties
Members get full access to every article.
